- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 1 | GlobeNewswire (USA) | ||
| Fr | KTTA-Aktie erreicht 52-Wochen-Tief bei 3,19 US-Dollar | 4 | Investing.com Deutsch | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | KTTA stock touches 52-week low at $3.19 amid market challenges | 1 | Investing.com | ||
| 13.11. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.11. | KTTA stock touches 52-week low at $3.4 amid market challenges | 1 | Investing.com | ||
| 25.10. | KTTA stock touches 52-week low at $3.6 amid market challenges | 2 | Investing.com | ||
| 07.10. | Pasithea Therapeutics files to sell 3.74M shares of common stock for holders | 2 | Seeking Alpha | ||
| 27.09. | Pasithea Therapeutics drops 19% on $5M private placement | 2 | Seeking Alpha | ||
| 27.09. | Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 6 | GlobeNewswire (USA) | ||
| 26.09. | Pasithea Announces Positive Initial Data From Phase 1 Trial Of PAS-004 In Advanced Cancer; Stock Up | 2 | RTTNews | ||
| 26.09. | Why Is Pasithea Therapeutics Stock Surging On Thursday? | 2 | Benzinga.com | ||
| 26.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.09. | Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 112 | GlobeNewswire (Europe) | -- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No treatment-related... ► Artikel lesen | |
| 09.09. | Pasithea reports positive results in PAS-004 toxicity studies | 2 | Investing.com | ||
| 09.09. | Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies | 1 | GlobeNewswire (USA) | ||
| 04.09. | KTTA stock touches 52-week low at $4.36 amid market challenges | 3 | Investing.com | ||
| 03.09. | Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
| 28.08. | Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 13.08. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 26.06. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| OCUGEN | 0,866 | -0,52 % | Ocugen Receives Orphan Medicinal Product Designation From EMA For OCU410ST | ||
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,725 | -5,22 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,720 | -3,10 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| GENPREX | 1,820 | 0,00 % | Genprex links with University of Michigan on lung cancer treatment | ||
| ONCOLYTICS BIOTECH | 0,890 | -5,82 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,400 | +1,30 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,960 | +1,05 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,280 | +0,48 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,210 | -0,75 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,700 | -0,59 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,590 | +0,88 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,000 | 0,00 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level |
PASITHEA THERAPEUTICS CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,180 Euro und damit -0,31 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.
